Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06768697 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Immunogenicity Evaluation of the Recombinant Flagellin Protein Adjuvant

StatusNot Yet Recruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 10, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
The goal of this clinical trial is to learn if the SARS-CoV-2 subunit mucosal vaccine with the recombinant flagellin protein adjuvant works to Prevent COVID-19 infection. It will also learn about the Safety and immunogenicity of the vaccine.
Trial Details
NCT Number NCT06768697
Lead Sponsor Shanghai Public Health Clinical Center
Conditions
(from sponsor)		 COVID - 19
Related terms COVID-19
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov